SARS-COV-2 infection outcomes in patients with congenital generalized lipodystrophy
Open Access
- 13 June 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Diabetology & Metabolic Syndrome
- Vol. 13 (1), 1-9
- https://doi.org/10.1186/s13098-021-00680-1
Abstract
Background A new strain of human coronavirus (HCoV) spread rapidly around the world. Diabetes and obesity are associated with a worse prognosis in these patients. Congenital Generalized Lipodystrophy (CGL) patients generally have poorly controlled diabetes and require extremely high doses of insulin. There is no documentation in the literature of cases of COVID in CGL patients. Thus, we aimed to evaluate the prevalence of SARS-CoV-2 infection in CGL patients, and the association of their clinical and metabolic characteristics and outcomes. Methods This is a cross-sectional study carried out between July and October 2020. Clinical data collected were respiratory or other flu-like symptoms, need of hospitalization in the last three months, CGL comorbidities, and medications in use. Cholesterol, triglycerides, glycohemoglobin A1c levels, anti-SARS-CoV-2 antibodies and nasopharyngeal swab for RT-qPCR were also obtained in all CGL patients. Mann-Whitney U test was used to analyze the characteristics of the participants, verifying the non-adherence of the data to the Gaussian distribution. In investigating the association between categorical variables, we used Pearson's chi-square test and Fisher's exact test. A significance level of 5% was adopted. Results Twenty-two CGL patients were assessed. Eight subjects (36.4%) had reactive anti-SARS-CoV-2 antibodies. Only one of these, also presented detectable RT-qPCR. Five individuals (62.5%) were women, median age of 13.5 years (1 to 37). Symptoms like fever, malaise, nausea, diarrhea and chest pain were present, and all asymptomatic patients were children. All subjects had inadequate metabolic control, with no difference between groups. Among positive individuals there was no difference between those with AGPAT2 (75%) and BSCL2 gene mutations (25%) (p > 0.05). No patient needed hospitalization or died. Conclusions We described a high prevalence of SARS-CoV-2 infection in CGL patients with a good outcome in all of them. These findings suggest that at least young CGL patients infected by SARS-COV-2 are not at higher risk of poor outcome, despite known severe metabolic comorbidities.Keywords
This publication has 53 references indexed in Scilit:
- Early commitment of cardiovascular autonomic modulation in Brazilian patients with congenital generalized lipodystrophyBMC Cardiovascular Disorders, 2018
- High prevalence of Berardinelli-Seip Congenital Lipodystrophy in Rio Grande do Norte State, Northeast BrazilDiabetology & Metabolic Syndrome, 2017
- Estimating the prevalence of generalized and partial lipodystrophy: findings and challengesDiabetes, Metabolic Syndrome and Obesity, 2017
- Overweight among children and adolescent with type I diabetes mellitus: prevalence and associated factorsDiabetology & Metabolic Syndrome, 2016
- Clinical and laboratory data of a large series of patients with congenital generalized lipodystrophyDiabetology & Metabolic Syndrome, 2016
- Evolution of the immune system in humans from infancy to old ageProceedings. Biological sciences, 2015
- Congenital generalized lipodystrophies—new insights into metabolic dysfunctionNature Reviews Endocrinology, 2015
- Towards a mechanistic understanding of lipodystrophy and seipin functionsBioscience Reports, 2014
- Leptin: molecular mechanisms, systemic pro-inflammatory effects, and clinical implicationsArchives of Endocrinology and Metabolism, 2012
- Phenotypic and Genetic Heterogeneity in Congenital Generalized LipodystrophyJournal of Clinical Endocrinology & Metabolism, 2003